Table 1. Summary of F statistics and Mean Values.
| F statistics |
Means |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aripiprazole | Methamphetamine | Methamphetamine × Aripiprazole |
Aripipriazole (0 mg) and Methamphetamine |
Aripipriazole (20 mg) and Methamphetamine |
|||||||||
| Measure | (df1,5) | (df4,20) | (df4,20) | 0 mg | 2.5 mg | 5 mg | 10 mg | 15 mg | 0 mg | 2.5 mg | 5 mg | 10 mg | 15 mg |
| Discrimination Performance | |||||||||||||
| Percent Drug-Appropriate Responiding | 12.5 | 10.5 | 0.8 | 16.1 | 20.8 | 76.0 | 85.3 | 94.8 | 5.2 | 20.6 | 50.0* | 53.1* | 65.0* |
| Inventory | |||||||||||||
| A | 8.4 | 2.6 | 0.9 | 1.3 | 1.9 | 2.4 | 3.2 | 3.8 | 0.8 | 1.1 | 1.3* | 3.1 | 2.4* |
| BG | 21.3 | 2.0 | 0.9 | 4.9 | 5.1 | 5.9 | 6.6 | 7.0 | 4.5 | 4.0 | 4.9* | 6.5 | 6.1* |
| Adjective-Rating Scale | |||||||||||||
| Stimulant Scale | 11.2 | 4.6 | 3.1 | 3.3 | 4.3 | 5.8 | 8.8 | 12.4 | 3.1 | 3.3 | 4.3 | 7.2 | 7.4* |
| Sedative Scale | 18.5 | 1.9 | 0.8 | 3.6 | 4.2 | 1.3 | 1.2 | 0.8 | 4.0 | 5.0 | 3.0* | 3.1* | 2.0* |
| Drug-Effect Questionnaire | |||||||||||||
| High | 3.4 | 3.2 | 3.7 | 0.9 | 0.5 | 2.5 | 3.3 | 5.2 | 1.0 | 0.9 | 2.0 | 1.1* | 1.5* |
| Irregular-Racing Heartbeat | 4.2 | 2.9 | 3.5 | 1.1 | 0.8 | 3.3 | 7.9 | 8.8 | 0.8 | 1.7 | 3.1 | 2.0* | 6.9 |
| Talkative-Friendly | 8.8 | 3.3 | 1.9 | 1.0 | 2.2 | 10.1 | 16.0 | 22.6 | 0.9 | 1.3 | 2.6* | 10.9* | 12.8* |
| Any Effect | 3.7 | 4.2 | 0.2 | 8.8 | 12.5 | 19.5 | 26.2 | 33.0 | 2.8 | 8.1 | 10.6 | 20.3 | 20.8* |
| Good Effects | 5.7 | 3.5 | 0.6 | 2.1 | 6.5 | 17.7 | 23.0 | 30.5 | 1.1 | 2.3 | 5.9* | 19.3 | 19.0* |
| Willing to Pay For | 3.7 | 2.9 | 0.9 | 9.8 | 9.5 | 25.6 | 27.1 | 34.0 | 1.9 | 9.5 | 4.1* | 23.3 | 23.9 |
| Restless | 0.0 | 3.2 | 1.2 | 1.0 | 2.3 | 4.0 | 10.2 | 16.7 | 3.5 | 5.4 | 4.3 | 13.1 | 6.8* |
| Rush | 3.9 | 2.9 | 1.8 | 1.0 | 3.9 | 9.4 | 8.8 | 14.2 | 2.5 | 1.9 | 3.4* | 11.4 | 6.8* |
| Active-Alert-Energetic | 11.8 | 2.5 | 0.8 | 1.9 | 3.0 | 14.8 | 19.7 | 25.9 | 1.0 | 1.9 | 3.6* | 18.3 | 16.6* |
| Digit-Symbol-Substitution-Task | |||||||||||||
| Number of Trials Attempted | 9.2 | 6.6 | 0.6 | 68.8 | 69.1 | 71.5 | 71.9 | 73.3 | 64.7* | 67.4 | 67.8* | 70.8 | 70.1* |
| Number of Trials Correct | 21.0 | 8.6 | 0.8 | 66.2 | 66.3 | 68.6 | 69.3 | 70.2 | 60.3* | 63.8 | 64.4* | 66.9 | 67.9 |
| Cardiovascular Measures | |||||||||||||
| Systolic Pressure | 3.4 | 10.4 | 2.1 | 114.3 | 115.4 | 121.8 | 124.1 | 127.0 | 117.7 | 116.4 | 117.0* | 120.4* | 124.7 |
| Diastolic Pressure | 8.3 | 5.9 | 2.5 | 70.0 | 71.5 | 73.1 | 74.7 | 77.7 | 71.9 | 71.5 | 70.8* | 71.3* | 74.2* |
| Heart Rate | 3.0 | 2.8 | 4.0 | 72.5 | 72.1 | 77.9 | 78.4 | 83.5 | 78.6* | 80.4* | 80.3 | 78.2 | 78.8* |
Summary statistics are not included for a particular measure if the two-factor ANOVA failed to reveal a significant effect of Aripiprazole, Methamphetamine or interaction of Aripiprazole and Methamphetamine. Discrimination data were analyzed as the total percent of points allocated to the drug option across the five hour session. All other data were analyzed as area-under-the-time-action curve (AUC). A = Amphetamine; BG = Benzedrine Group. Bold and underlined F values are statistically significant (p ≤ .05). Bold mean values are significantly different from the corresponding placebo values (i.e., 0 mg methamphetamine). An asterisk indicates a significant difference between the values under 0 mg and 20 mg aripiprazole conditions at the indicated methamphetamine dose